Alkermes plc. — Director's Dealing 2024

Feb 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2024-02-08

Reporting Person: Hopkinson Craig C. (EVP R&D, Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-08	Ordinary Shares	A	46658	—	Acquired	103217	Direct
2024-02-08	Ordinary Shares	F	15280	$26.77	Disposed	87937	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-17	Employee Stock Option (Right to Buy)	$58.40	J	1599	Acquired	2027-06-07	Ordinary Shares (1599)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$65.94	J	1089	Acquired	2028-02-16	Ordinary Shares (1089)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$31.93	J	2133	Acquired	2029-02-21	Ordinary Shares (2133)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$20.03	J	3376	Acquired	2030-02-20	Ordinary Shares (3376)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	201	Acquired		Ordinary Shares (201)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$19.34	J	3929	Acquired	2031-02-22	Ordinary Shares (3929)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	481	Acquired		Ordinary Shares (481)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$24.59	J	2790	Acquired	2032-02-18	Ordinary Shares (2790)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	523	Acquired		Ordinary Shares (523)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$26.82	J	2412	Acquired	2033-02-23	Ordinary Shares (2412)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	603	Acquired		Ordinary Shares (603)	Direct

Footnotes

F1: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs.

F2: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3: These options are fully vested in accordance with their terms.

F4: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

F5: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F7: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

F8: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F9: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

F10: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F11: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

F12: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.